公开(公告)号：US20240423987A1

公开(公告)日：2024-12-26

申请号：US18825566

申请日：2024-09-05

Applicant: Mirati Therapeutics, Inc.

Inventor： Lars Daniel Engstrom ,  Peter Olson ,  James Gail Christensen

IPC: A61K31/519 ,  A61K31/416 ,  A61K31/502 ,  A61K31/517 ,  A61P35/00

Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with KRASG12C inhibitors.

公开(公告)号：US20240423984A1

公开(公告)日：2024-12-26

申请号：US18694921

申请日：2022-10-04

Applicant: MIRATI THERAPEUTICS, INC.

Inventor： Jill Hallin ,  James Gail Christensen ,  Vickie Bowcut ,  Peter Olson

IPC: A61K31/519 ,  A61K31/497 ,  A61P35/00

Abstract: The present invention relates to combination therapies for treating KRas G12D cancers, In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a. therapeutically effective amount of a combination of a SHP-2 inhibitor and a KRAS G12D inhibitor of Formula (I), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use thereof.

公开(公告)号：US11890285B2

公开(公告)日：2024-02-06

申请号：US17029654

申请日：2020-09-23

Applicant: Mirati Therapeutics, Inc.

Inventor： David Briere ,  James Gail Christensen ,  Peter Olson

IPC: A61K31/519 ,  A61P35/04 ,  C07K16/28

CPC classification number: A61K31/519 ,  A61P35/04 ,  C07K16/2818 ,  C07K16/2827

Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a an agent that blocks Programmed Death-1 receptor (PD-1) and Programmed Death Ligand-1 (PD-L1) signaling and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, kits comprising the compositions and methods of use therefor.

公开(公告)号：US20220096482A1

公开(公告)日：2022-03-31

申请号：US17275177

申请日：2019-09-09

Applicant: Mirati Therapeutics, Inc.

Inventor： James Gail Christensen ,  Ruth Wei Aranda ,  Lars Daniel Engstrom ,  Jill Hallin ,  Peter Olson

IPC: A61K31/519 ,  A61K31/506 ,  A61P35/00

Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a CDK 4/6 inhibitor and a KRAS G12C inhibitor of Formula (I), Formula (I-A) or Formula (I-B), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.

公开(公告)号：US20200331911A1

公开(公告)日：2020-10-22

申请号：US16917128

申请日：2020-06-30

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma, Inc.

Inventor： Matthew Arnold Marx ,  James Gail Christensen ,  Christopher Ronald Smith ,  John P. Fischer ,  Aaron Craig Burns

IPC: C07D471/04 ,  A61P35/00 ,  C07D519/00

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20180072723A1

公开(公告)日：2018-03-15

申请号：US15814279

申请日：2017-11-15

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： James F. Blake ,  Laurence E. Burgess ,  Mark Joseph Chicarelli ,  James Gail Christensen ,  Jay Bradford Fell ,  John P. Fischer ,  John J. Gaudino ,  Erik James Hicken ,  Ronald Jay Hinklin ,  Matthew Randolf Lee ,  Matthew Arnold Marx ,  Macedonio J. Mejia ,  Martha E. Rodriguez ,  Pavel Savechenkov ,  Tony P. Tang ,  Guy P.A. Vigers ,  Henry J. Zecca

IPC: C07D471/04

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20240408098A1

公开(公告)日：2024-12-12

申请号：US18694848

申请日：2022-10-04

Applicant: MIRATI THERAPEUTICS, INC.

Inventor： Jill Hallin ,  James Gail Christensen ,  Vickie Bowcut ,  Peter Olson

IPC: A61K31/519 ,  A61K31/4439 ,  A61P35/00

Abstract: The present invention relates to combination therapies for treating KRas G12D cancers: in particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a PI3Ka inhibitor and a KRas G12D inhibitor, pharmaceutical compositions comprising a such compositions, kits comprising such compositions and methods of use thereof.

公开(公告)号：US20230383359A1

公开(公告)日：2023-11-30

申请号：US18032492

申请日：2021-10-21

Applicant: Mirati Therapeutics, Inc.

Inventor： James Gail Christensen ,  Andrew Chi ,  Thian Kheoh

IPC: C12Q1/6886 ,  A61K31/519 ,  A61K45/06 ,  A61P35/00

CPC classification number: C12Q1/6886 ,  A61K31/519 ,  A61K45/06 ,  A61P35/00 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: The present invention relates to methods for treatment of lung cancers, in particular non-small cell lung cancer (NSCLC), wherein lung cancers have both a KRAS G12C mutation and an STK11 mutation, with adagrasib (MRTX849).

公开(公告)号：US20220331323A1

公开(公告)日：2022-10-20

申请号：US17713455

申请日：2022-04-05

Applicant: Mirati Therapeutics, Inc.

Inventor： Lars Daniel Engstrom ,  Peter Olson ,  James Gail Christensen

IPC: A61K31/519 ,  A61P35/00 ,  A61K31/506

Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with CDK4/6 inhibitors.

公开(公告)号：US11220509B2

公开(公告)日：2022-01-11

申请号：US17219379

申请日：2021-03-31

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  Matthew Randolph Lee ,  Thomas P. Bobinski ,  Aaron Craig Burns ,  Nidhi Arora ,  James Gail Christensen ,  John Michael Ketcham

IPC: C07D487/04

Abstract: The present disclosure relates to compounds of Formula (I), or pharmaceutically, acceptable salts thereof, that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present disclosure relates to compounds, or pharmaceutically acceptable salts thereof pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising compounds of Formula (I), or pharmaceutically acceptable salts thereof.